Natco Pharma
Ticker > Company >

Natco Pharma share price

Natco Pharma Ltd.

NSE: NATCOPHARM BSE: 524816 SECTOR: Pharmaceuticals & Drugs  1.96 L   736   160

853.50
-8.70 (-1.01%)
NSE: Today, 02:14 PM

Price Summary

Today's High

₹ 865.95

Today's Low

₹ 847.4

52 Week High

₹ 1594

52 Week Low

₹ 726.8

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 15287.03 Cr.

Enterprise Value

₹ 13703.23 Cr.

No. of Shares

17.91 Cr.

P/E

9.11

P/B

1.96

Face Value

₹ 2

Div. Yield

0.7 %

Book Value (TTM)

₹  435.38

CASH

₹ 1856.9 Cr.

DEBT

₹ 273.1 Cr.

Promoter Holding

49.56 %

EPS (TTM)

₹  93.7

Sales Growth

14.73%

ROE

28.63 %

ROCE

33.11%

Profit Growth

41.62 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Natco Pharma Ltd.

Molnunat Lenvanix Veenat Erlonat Sorafenat Gefinat Hepcinat Velpanat Natdac Bortenat Evermil Cabometyx Abirapro Lenalid Bendit Dasanat Pazopanib Sunitinib Axitinib Bosentan Imatinib Osimertinib Pomalidomide Regorafenib Temozolomide Trabectedin Voriconazole Enzalutamide Palbociclib Ribociclib Venetoclax Zanubrutinib

Index Presence

The company is present in 25Indices.

NFTSML250MOMQ100

Nifty Smallcap250 Momentum Quality 100 index
46087.6
  255.449999999997 (0.557359844563243%)

NFTMIDSMLHEALTH

Nifty MidSmall Healthcare
45022.2
  -160.900000000001 (-0.356106597378225%)

NIFTY500

Nifty 500
23209.5
  19.25 (0.0830090231886293%)

NIFTYPHARMA

Nifty Pharma
22224.2
  -117 (-0.523696130915086%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
20067.25
  82.4000000000015 (0.412312326587405%)

NIFTYSMALL

NIFTY Smallcap 100
18116.05
  126.149999999998 (0.701226799481924%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
17882.2
  49.8500000000022 (0.279548124616236%)

NIFTYSMALLCAP250

Nifty Smallcap 250
17241
  96.1500000000015 (0.560809805860085%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
16195.55
  31.7999999999993 (0.196736524630725%)

NY500MUL50:30:20

Nifty500 Multicap India Manufacturing 50:30:20
15706.4
  -19.8000000000011 (-0.125904541465838%)

NFT500EQUAL

Nifty 500 Equal Weight
14483.85
  63.1000000000004 (0.437563926980222%)

NIFTYTOTALMCAP

Nifty Total Market index
13065.25
  14 (0.107269418638056%)

NIFTYSMALLCAP50

Nifty Smallcap 50
8702.15
  54.4499999999989 (0.629647189426086%)

SHARIAH500

Nifty500 Shariah
7190.5
  -4.60000000000036 (-0.0639323984378271%)

NIFTYFULLMIDCAP100

NIFTY FULL MIDCAP 100
5987.56
  -42.7999999999993 (-0.709742038617911%)

SMLCAP

S&P Bse Small Cap
53861.06
  312.57 (0.583713938525632%)

BSE HC

S&P Bse Healthcare
44742.42
  -180.150000000001 (-0.401023360862929%)

BSE500

S&P Bse 500
36442.03
  23.4099999999962 (0.0642803049648588%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
12414.1
  73.2299999999996 (0.593394144821224%)

MSL400

S&P Bse 400 MidSmallCap
12160.33
  45.1000000000004 (0.372258718984297%)

BSE1000

Bse 1000
10860.8
  10.1599999999999 (0.0936350298231137%)

ALLCAP

S&P Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

SHA500

S&P Bse 500 Shariah
9113.66
  125.5 (1.39628133010539%)

SMLSEL

S&P Bse SmallCap Select Index
8083.6
  34.9500000000007 (0.434234312586601%)

SML250

S&P Bse 250 SmallCap
6899.91
  36.9200000000001 (0.537957945443601%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year14.73%
3 Year32.31%
5 Year17.99%

Profit Growth

1 Year41.62%
3 Year136.94%
5 Year31.28%

ROE%

1 Year28.63%
3 Year22.78%
5 Year15.91%

ROCE %

1 Year33.11%
3 Year26.21%
5 Year18.38%

Debt/Equity

0.0372

Price to Cash Flow

9.2

Interest Cover Ratio

114.5714

CFO/PAT (5 Yr. Avg.)

0.915454781153511

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 49.56 0.00
Mar 2025 49.56 0.00
Dec 2024 49.62 0.00
Sep 2024 49.62 0.00
Jun 2024 49.71 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 136.944244136692% for the Past 3 years.
  • The company has shown a good revenue growth of 32.308587412923% for the Past 3 years.
  • Company has been maintaining healthy ROE of 22.7824333333333% over the past 3 years.
  • Company has been maintaining healthy ROCE of 26.2147% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 114.5714.
  • The Company has been maintaining an effective average operating margins of 32.9143107966404% in the last 5 years.
  • Company’s PEG ratio is 0.218868051558234.
  • The company has an efficient Cash Conversion Cycle of 13.8015 days.
  • Company has a healthy liquidity position with current ratio of 5.4222.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 5.27039081423962.

 Limitations

 Looks like the company does not have any serious limitations.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 1236.9 1292.6 407.6 1157.4 1192.7
Total Expenditure 473.9 501.9 378.2 596.2 653
Operating Profit 763 790.7 29.4 561.2 539.7
Other Income 39.8 51.4 168 62.1 59.6
Interest 4.4 3 3.4 8.8 2.6
Depreciation 40.4 42.2 43.7 93.7 53.8
Exceptional Items 0 0 0 0 0
Profit Before Tax 758 796.9 150.3 520.8 542.9
Tax 121.7 135.8 25.4 92.7 78.8
Profit After Tax 636.3 661.1 124.9 428.1 464.1
Adjusted EPS (Rs) 35.55 36.93 6.98 23.92 25.93

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 1653.5 1767.8 2351 3568.9 4094.5
Total Expenditure 1238.3 1554.8 1530.2 1931.9 1952.4
Operating Profit 415.2 213 820.8 1637 2142.1
Other Income 103.5 94.6 109.4 104.7 323.5
Interest 11.3 13.3 8.6 14.5 19.6
Depreciation 115.2 138.4 150.9 171.9 220
Exceptional Items 0 0 0 0 0
Profit Before Tax 392.2 155.9 770.7 1555.3 2226
Tax 82.7 16.8 133.6 248.7 375.6
Net Profit 309.5 139.1 637.1 1306.6 1850.4
Adjusted EPS (Rs.) 16.96 7.62 34.91 72.99 103.37

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 36.5 36.5 36.5 35.8 35.8
Total Reserves 4054.6 4155.4 4665.5 5556.5 7298.1
Borrowings 0 0 0 0 0
Other N/C liabilities 142.9 134.9 116.9 69 30.4
Current liabilities 518.5 651.2 569 885.6 864.6
Total Liabilities 4752.5 4978 5387.9 6546.9 8228.9
Assets
Net Block 2005.9 2174.2 2233.8 2286.7 2516.8
Capital WIP 223.4 128.7 62.8 133.9 225.3
Intangible WIP 0 0 0 0 0
Investments 294.9 430.4 517.6 577.8 565.1
Loans & Advances 55.6 72.4 78.8 111.5 73
Other N/C Assets 4.2 4.6 0.2 26.6 160.7
Current Assets 2168.5 2167.7 2494.7 3410.4 4688
Total Assets 4752.5 4978 5387.9 6546.9 8228.9
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 392.2 155.9 770.7 1555.3 2226
Adjustment 58.4 118.5 85.4 150.9 -20.4
Changes in Assets & Liabilities -190.2 -184.2 76.7 -257.8 -199
Tax Paid -76.9 -32.5 -148.4 -252 -344.6
Operating Cash Flow 183.5 57.7 784.4 1196.4 1662
Investing Cash Flow -3.2 -92.5 -436.6 -960.5 -1443.9
Financing Cash Flow -183.1 35.6 -346.8 -237.3 -212.4
Net Cash Flow -2.8 0.8 1 -1.4 5.7

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 49.71 49.62 49.62 49.56 49.56
devendranth alapati 0.01 0.01 0.01 0.01 0.01
durga devi nannapaneni 1.98 1.98 1.98 1.98 1.98
kantamani ratna kumar 0.06 0.03 0.03 0.03 0.03
natco aqua limited 0.01 0.01 0.01 0.01 0.01
natsoft information syste... 8.81 8.81 8.81 8.81 8.81
ndl infratech private lim... 0.05 0.05 0.05 0.05 0.05
neelima sita nannapaneni 0.10 0.10 0.10 0.10 0.10
rajeev nannapaneni 0.63 0.63 0.63 0.60 0.60
sanjay nannapaneni - - - 0.18 0.18
satya vani nannapaneni - - - 0.23 0.23
t ananda babu 0.23 0.23 0.23 0.23 0.23
t anila 0.33 0.32 0.32 0.32 0.32
time cap pharma labs priv... - - - 9.59 9.59
tummala jansi 0.04 0.04 0.04 0.04 0.04
v c nannapaneni 15.66 15.66 15.66 15.66 15.66
venkata satya swathi kant... 8.92 8.92 8.92 8.90 8.90
vidyadhari tummala 0.25 0.21 0.21 0.21 0.21
vistra itcl india limited... - - - 2.28 2.28
vistra itcl india limited... - - - 0.33 0.33
ramakrishna rao nannapane... 0.42 0.42 0.42 - -
time cap pharma labs pri... 9.59 9.59 9.59 - -
vistra itcl india limited... - - 2.28 - -
vistra itcl india limited... 0.33 0.33 0.33 - -
vistra itcl india limited... 2.28 2.28 - - -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 50.29 50.38 50.38 50.44 50.44
akash bhansali - - - - 1.01
belgrave investment fund 1.92 1.92 1.92 2.31 2.31
investor education and pr... 0.48 0.47 - 0.48 0.50
life insurance corporatio... 3.69 - - - 2.29
tata mutual fund- tata eq... - - 1.28 1.27 1.27
akash bhanshali 1.01 1.01 1.01 1.01 -
life insurance corporatio... - - - 2.29 -
investor education and pr... - - 0.48 - -
life insurance corporatio... - 3.04 2.29 - -
tata nifty 500 multicap i... - 1.22 - - -
tata nifty midsmall healt... 1.19 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit ICRA
Credit ICRA
TYPE AGENCY Link
TYPE AGENCY Link
Research Way 2 Wealth
Research Geojit
Research Geojit
Research Report By:
Research BP Wealth
Research Nirmal Bang Institutional

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY23
Concall Q4FY22
Concall Q3FY24
Concall Q2FY24
Concall Q1FY25
Concall Q1FY24
Concall Q1FY23
Concall Q1FY21
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY21
Presentation Q4FY20
Presentation Q3FY24
Presentation Q3FY22
Presentation Q2FY24
Presentation Q2FY23
Presentation Q2FY22
Presentation Q2FY21
Presentation Q1FY24
Presentation Q1FY22
Presentation Q1FY21

Company News

Natco Pharma informs about press release 10 Sep, 2:50 PM NATCO Pharma informs about press release 20 Aug, 11:49 AM NATCO Pharma launches Bosentan tablets for oral suspension 20 Aug, 11:28 AM Natco Pharma - Quaterly Results 12 Aug, 1:42 PM Natco Pharma - Quaterly Results 12 Aug, 1:42 PM Natco Pharma - Quaterly Results 12 Aug, 1:42 PM USFDA issues EIR to Natco Pharma’s Hyderabad API division 25 Jul, 4:30 PM Natco Pharma gets nod to incorporate wholly owned subsidiary in South Africa 24 Jul, 11:00 AM Natco Pharma informs about acquisition 23 Jul, 5:10 PM USFDA concludes inspection at Natco Pharma’s Kothur pharma division 20 Jun, 10:20 AM USFDA concludes inspection at Natco Pharma’s Hyderabad API manufacturing plant 13 Jun, 4:44 PM Natco Pharma - Quaterly Results 28 May, 3:46 PM Natco Pharma - Quaterly Results 28 May, 3:46 PM Natco Pharma - Quaterly Results 28 May, 3:46 PM Natco Pharma submits board meeting intimation 12 May, 6:20 PM NATCO Pharma informs about change in management 31 Mar, 3:16 PM Natco Pharma informs about change in management 3 Mar, 6:08 PM Natco Pharma informs about analyst meet 27 Feb, 5:09 PM NATCO Pharma informs about analyst meet 24 Feb, 5:25 PM Natco Pharma - Quaterly Results 12 Feb, 4:03 PM Natco Pharma - Quaterly Results 12 Feb, 4:03 PM Natco Pharma - Quaterly Results 12 Feb, 4:03 PM Natco Pharma submits analyst meet intimation 10 Feb, 2:51 PM Natco Pharma receives approval for ANDA for Bosentan tablets 10 Feb, 11:30 AM NATCO Pharma informs about press release 30 Jan, 11:38 AM Natco Pharma gets ANDA approval for Everolimus tablets for oral suspension 30 Jan, 9:59 AM NATCO Pharma informs about sustainability report 9 Dec, 1:05 PM Natco Pharma informs about details of loss of certificate 30 Nov, 5:39 PM Natco Pharma - Quaterly Results 12 Nov, 2:30 PM Natco Pharma - Quaterly Results 12 Nov, 2:30 PM Natco Pharma - Quaterly Results 12 Nov, 2:30 PM NATCO Pharma informs about board meeting 28 Oct, 5:32 PM NATCO Pharma informs about regulatory update 7 Oct, 9:51 AM Natco Pharma’s arm makes $8 million investment in eGenesis 4 Sep, 12:56 PM Natco Pharma informs about disclosure 28 Aug, 1:19 PM Natco Pharma informs about earnings call transcript 21 Aug, 4:58 PM Natco Pharma - Quaterly Results 12 Aug, 2:00 PM Natco Pharma - Quaterly Results 12 Aug, 2:00 PM Natco Pharma - Quaterly Results 12 Aug, 2:00 PM Natco Pharma informs about loss of share certificate 3 Aug, 3:52 PM NATCO Pharma informs about demise of independent director 31 Jul, 12:03 PM NATCO Pharma informs about issuance of duplicate share certificates 29 Jul, 5:16 PM Natco Pharma informs about change in management 27 Jul, 4:02 PM Natco Pharma informs about press release 28 May, 5:10 PM Natco Pharma - Quaterly Results 27 May, 4:42 PM Natco Pharma - Quaterly Results 27 May, 4:42 PM Natco Pharma - Quaterly Results 27 May, 4:42 PM NATCO Pharma informs about earnings call 15 May, 5:19 PM Natco Pharma informs about details of loss of certificate 14 May, 5:33 PM NATCO Pharma informs about disclosure 23 Apr, 4:50 PM

Natco Pharma Stock Price Analysis and Quick Research Report. Is Natco Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Natco Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Natco Pharma has a PE ratio of 9.14546616903263 which is low and comparatively undervalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Natco Pharma has ROA of 25.0464% which is a good sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Natco Pharma has a Current ratio of 5.4222.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Natco Pharma has a ROE of 28.6302%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Natco Pharma has a Debt to Equity ratio of 0.0372 which means that the company has low proportion of debt in its capital.

  • Sales growth: Natco Pharma has reported revenue growth of 14.7272% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Natco Pharma for the current financial year is 52.3165221638784%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Natco Pharma is Rs 6 and the yield is 0.7026%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Natco Pharma is Rs 93.6967. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Natco Pharma in Ticker for free. Also, one can get the intrinsic value of Natco Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Natco Pharma FAQs

Q1. What is Natco Pharma share price today?
Ans: The current share price of Natco Pharma is Rs 856.9.

Q2. What is the market capitalisation of Natco Pharma?
Ans: Natco Pharma has a market capitalisation of Rs 15347.9247603 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Natco Pharma?
Ans: The PE ratio of Natco Pharma is 9.14546616903263 and the P/B ratio of Natco Pharma is 1.96818156239485, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Natco Pharma share?
Ans: The 52-week high share price of Natco Pharma is Rs 1594, and the 52-week low share price of Natco Pharma is Rs 726.8.

Q5. Does Natco Pharma pay dividends?
Ans: Currently, Natco Pharma pays dividends. Dividend yield of Natco Pharma is around 0.7026%.

Q6. What are the face value and book value of Natco Pharma shares?
Ans: The face value of Natco Pharma shares is Rs 2, while the book value per share of Natco Pharma is around Rs 435.3765. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Natco Pharma?
Ans: Natco Pharma has a total debt of Rs 273.1 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Natco Pharma?
Ans: The ROE of Natco Pharma is 28.6302% and ROCE of Natco Pharma is 33.1148%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Natco Pharma a good buy for the long term?
Ans: The Natco Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Natco Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Natco Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Natco Pharma’s financials?
Ans: You can review Natco Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Natco Pharma

Natco Pharma Ltd Financials: Check Share price, Balance Sheet, Annual report and Quarterly Results for company analysis 

 

Welcome to the stock analysis page of Natco Pharma Ltd., where we provide a technical and comprehensive evaluation of the company's financial performance and growth potential. Our analysis is tailored for long-term stock investors, including doctors, who seek an in-depth understanding of the company's financial health. Our website offers pre-built screening tools, allowing investors to analyze specific parameters with ease. Annual reports and quarterly results are available as downloadable files on our website.

Natco Pharma Ltd Share Price

Track the share price trends of Natco Pharma Ltd. using our intuitive charts and real-time updates. Ticker platform provides historical data and analysis of the company's stock performance, enabling investors to make informed investment decisions.

Natco Pharma Ltd Balance Sheet

Evaluate the financial position of Natco Pharma Ltd. with our comprehensive balance sheet analysis. Utilize our premium features, including DCF Analysis, BVPS Analysis, Earnings Multiple approach, and DuPont Analysis, to calculate the company's fair value and growth potential accurately.

Natco Pharma Ltd Annual Report

Obtain the annual reports of Natco Pharma Ltd. from our website. These reports offer insights into the company's operational and financial performance, as well as strategic initiatives for the year. Ticker pre-built screening tools facilitate the filtering of reports based on specific parameters.

Natco Pharma Ltd Dividend

Stay updated on Natco Pharma Ltd.'s dividend payouts and dividend history with our user-friendly interface. Our website provides easy access to dividend-related information, allowing investors to review the company's past dividend payouts and consider them when making investment decisions.

Natco Pharma Ltd Quarterly Result

Access the quarterly results of Natco Pharma Ltd. through downloadable files available on our website. Ticker platform offers a comprehensive analysis of the company's financial performance, and our premium features, including DCF Analysis, Earnings Multiple Approach, and DuPont Analysis, enhance the evaluation of the company's growth prospects.

Natco Pharma Ltd Stock Price

Keep track of Natco Pharma Ltd.'s stock price movements utilizing our user-friendly charts and real-time updates. Our platform offers in-depth analysis of the company's historical price trends, enabling investors to make informed investment decisions.

Natco Pharma Ltd Price Chart

Visualize the stock price movements of Natco Pharma Ltd. through our detailed price charts. Ticker platform provides insights into the company's historical performance, and our premium features, including fair value calculation using DCF Analysis, Earnings Multiple, and DuPont Analysis, offer investors greater clarity on the company's financial health.

Natco Pharma Ltd News

Stay updated with the latest news and developments of Natco Pharma Ltd. with our comprehensive news aggregation platform. Our reliable sources gather the most relevant news, enabling investors to make informed investment decisions.

Natco Pharma Ltd Concall Transcripts

Access the conference call transcripts of Natco Pharma Ltd. through downloadable files available on our website. These transcripts provide valuable insights into the company's management discussions, milestones, and financial performance. Utilize our premium features, including DCF Analysis, Earnings Multiple Approach, and DuPont Analysis, to enhance the evaluation of the company's financial health.

Natco Pharma Ltd Investor Presentations

Explore the investor presentations of Natco Pharma Ltd. These presentations provide detailed overviews of the company's business operations, growth strategies, and financial performance. Our platform offers features to filter the presentations based on specific parameters, allowing users to identify relevant information for their investment decisions.

Natco Pharma Ltd Promoters

Get acquainted with the promoters of Natco Pharma Ltd., the individuals responsible for the company's growth and success. Ticker platform provides detailed information about the promoters, their backgrounds, and their contributions to the company's development.

Natco Pharma Ltd Shareholders

Understand the shareholders of Natco Pharma Ltd., including institutional investors and retail shareholders. The shareholder structure can provide valuable insights into the company's ownership patterns and potential market influence.

Natco Pharma Ltd ROCE

Return on Capital Employed (ROCE) is a key metric used to evaluate Natco Pharma Ltd's efficiency in generating returns from its capital investments. ROCE indicates how well the company utilizes its capital to generate profits for its shareholders. Investors can access the ROCE data for Natco Pharma Ltd conveniently located in the financials table or the ratio section provided on this page.

Natco Pharma Ltd EBITDA

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is a crucial measure of Natco Pharma Ltd's operational performance and profitability, excluding non-operating expenses. Analyzing EBITDA provides insights into the company's core operational earnings. The EBITDA data for Natco Pharma Ltd is readily accessible in the financials table or the ratio section on this page.

Natco Pharma Ltd DPS

Dividends Per Share (DPS) represents the portion of Natco Pharma Ltd's profits distributed to shareholders per outstanding share. DPS is an important metric for investors seeking regular dividend income. Investors can refer to the financials table or the ratio section provided on this page for Natco Pharma Ltd's DPS data.

Natco Pharma Ltd EPS

Earnings Per Share (EPS) offers insights into the portion of Natco Pharma Ltd's profit allocated to each outstanding share of its common stock. Analyzing EPS helps investors understand the company's profitability on a per-share basis. The EPS data for Natco Pharma Ltd can be viewed in the financials table or the dedicated ratio section above. 

Natco Pharma's Strengthening Equity and Liabilities

Steady Growth in Natco Pharma's Share Capital

Natco Pharma has demonstrated a gradual increase in its share capital, reaching Rs. 35.80 Cr. by March 2024, a move reflecting its strategic financial decisions aimed at reinforcing investor confidence.

Surge in Natco Pharma's Total Reserves

The total reserves of Natco Pharma have observed a significant rise from Rs. 3,833.10 Cr. in March 2020 to an impressive Rs. 5,556.50 Cr. by March 2024. This substantial growth indicates robust internal funding and profitability retention strategies.

Commitment to a Debt-Free Structure in Natco Pharma

Highlighting a strong financial discipline, Natco Pharma maintained a zero borrowing stance throughout the observed period, showcasing its commitment to sustaining operations without leveraging debt.

Asset Expansion and Investment Insight in Natco Pharma

Consistent Asset Growth in Natco Pharma

Natco Pharma's total assets have shown a healthy increase, moving from Rs. 4,646.70 Cr. in March 2020 to Rs. 6,546.90 Cr. by March 2024. This reflects the company's continual investment in asset accumulation for long-term value creation.

Strategic Investments by Natco Pharma

With investments growing to Rs. 577.80 Cr. by March 2024, Natco Pharma appears to be strategically bolstering its investment portfolio, potentially to diversify its revenue streams and enhance shareholder value.

This analysis represents the standalone balance sheet of Natco Pharma, signifying its financial health through consistent asset growth, no reliance on debt, and increased reserves.

Those interested in pharmaceutical sector investments might find Natco Pharma a notable case, given its solid financial foundation and strategic market positioning.

Read More
X